<SEC-DOCUMENT>0001654954-23-014763.txt : 20231127
<SEC-HEADER>0001654954-23-014763.hdr.sgml : 20231127
<ACCEPTANCE-DATETIME>20231127074836
ACCESSION NUMBER:		0001654954-23-014763
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231126
FILED AS OF DATE:		20231127
DATE AS OF CHANGE:		20231127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FSD Pharma Inc.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		231437333

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>fsd_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title>fsd_6k.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">Form 6-K</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO RULE 13a-16 OR 15d-16</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the month of: <strong><u>November 2023</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission File Number: <strong><u>001-39152</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FSD PHARMA INC.</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Translation of registrant&#8217;s name into English)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>199 Bay St., Suite 4000</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>Toronto, Ontario M5L 1A9, Canada</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive office)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Form 40-F &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FSD Pharma Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Registrant)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: November 27, 2023</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Nathan Coyle</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Nathan Coyle, Chief Financial Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">2</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:10%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit</strong></p></td> <td style="width:2%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Description</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="fsd_ex991.htm">99.1</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="fsd_ex991.htm">Press Release &#8211; November 27, 2023 - FSD Pharma Inc. Obtains Final Order for Plan of Arrangement</a></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fsd_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>fsd_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="fsd_ex991img4.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>FSD Pharma Inc. Obtains Final Order for Plan of Arrangement</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>TORONTO, November 27, 2023</strong>-- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("<strong>FSD Pharma</strong>" or the "<strong>Company</strong>"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it obtained a final order on November 24, 2023 from the Ontario Superior Court of Justice (Commercial List) (the &#8220;<strong>Final Order</strong>&#8221;) approving the previously-announced statutory plan of arrangement under section 182 of the <em>Business Corporations Act</em> (Ontario) (the "<strong>Arrangement</strong>") pursuant to which common shares in the capital of Celly Nutrition Corp. ("<strong>Celly Nu Shares</strong>"), will be distributed to the holders of class A multiple voting shares ("<strong>Class A Shares</strong>"), class B subordinate voting shares ("<strong>Class B Shares</strong>"), and warrants exercisable for the purchase of Class B Shares, provided the applicable warrant certificate entitles the holder thereof to receive distributions substantially similar to those received by holders of Class B Shares (&#8220;<strong>FSD Pharma Distribution Warrants</strong>&#8221;; together with the holders of Class A Shares and Class B Shares, the &#8220;<strong>FSD Pharma Securityholders</strong>&#8221;).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As previously disclosed in the Company&#8217;s press release dated November 21, 2023, at a special meeting of the FSD Pharma Securityholders, the special resolution to authorize the Arrangement was approved on November 20, 2023.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">It is currently anticipated that the Arrangement will close on or about November 29, 2023 subject to the satisfaction and/or waiver of all customary conditions precedent set forth in the arrangement agreement dated October 4, 2023 (&#8220;<strong>Arrangement Agreement</strong>&#8221;). Upon closing of the Arrangement, FSD Pharma Securityholders will receive one (1) Celly Nu Share for each Class A Share, Class B Share, and/or FSD Pharma Distribution Warrant held (&#8220;<strong>Consideration</strong>&#8221;).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Further details regarding the Consideration and the Arrangement are described in the management information circular dated October 20, 2023 (the "<strong>Circular</strong>"), the supplement to the Circular filed on November 15, 2023, and the Arrangement Agreement, each of which is available under the Company's profile on SEDAR+ at www.sedarplus.ca.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also pleased to announce a non-brokered private placement of Class A Shares (the &#8220;<strong>Offering</strong>&#8221;). The Company expects to offer up to 24 Class A Shares at a price of $1.90 per Class A Share, and expects that the entirety of the Offering will be subscribed for by certain of the existing holders of Class A Shares. All Class A Shares issued pursuant to the Offering will be subject to hold periods of four months and a day from the date of closing.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>About FSD Pharma</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. ("<strong>Lucid</strong>"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("<strong>Lucid-MS</strong>"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD is also focused on the research and development of UNBUZZD&#8482;, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. FSD maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Cautionary Note Regarding Forward-Looking Information</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. "Forward-looking information" includes, but is not limited to, statements with respect to the completion of the Agreement and the Transaction; the receipt of FSD Pharma Securityholder approval for the Arrangement; the receipt of final court approval of the Arrangement; the anticipated timing of the Meeting; the satisfaction or waiver of the closing conditions set out in the Arrangement Agreement, including receipt of all regulatory approvals; the anticipated closing date; and the satisfaction final approval of the Arrangement Agreement by the Canadian Securities Exchange and other activities, events or developments that the Company or Celly Nutrition Corp. expects or anticipates will or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as "plans", "expects", "intends", "estimates", "intends", "anticipates", or "believes" or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Such forward-looking information and statements are based on numerous assumptions, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Arrangement Agreement, including the anticipated closing date; that general business and economic conditions will not change in a material adverse manner. Although the assumptions made by the Company or Celly Nutrition Corp. in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate. Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual events or results in future periods to differ materially from any projections of future events or results expressed or implied by such forward-looking information or statements, including, among others: the diversion of management time on Arrangement-related issues; reliance on key management and other personnel; potential downturns in economic conditions; actual, and risks generally associated with the biotechnology or nutritional supplement industry, changes in laws and regulations, community relations and delays in obtaining other approvals. Although the Company and Celly Nutrition Corp. have attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company or Celly Nutrition Corp. undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws. Additional information relating to FSD Pharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov. None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended (the "<strong>U.S. Securities Act</strong>"), or any state securities laws, and any securities issuable in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.</em></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Contacts:</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>FSD Pharma Inc.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, FSD Pharma Inc.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Email: <u>Zsaeed@fsdpharma.com</u></a></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Telephone: (416) 854-8884</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Investor Relations</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Email: <u>ir@fsdpharma.com</u></a>, <u>info@fsdpharma.com</u></a></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Website: <u>www.fsdpharma.com</u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>ClearThink</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Email: <u>nyc@clearthink.capital</u></a></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Telephone: (917) 658-7878</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>SOURCE:</strong>FSD Pharma Inc.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>fsd_ex991img4.jpg
<TEXT>
begin 644 fsd_ex991img4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !C ,0# 2(  A$! Q$!_\0
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MCG8?#WX<7'A_4HC,W]H23Q=?E1DCX_[Z#'\:* /ERBBB@#IQX^\=J J^-->
M'  U*;C_ ,>I/^%@>//^AVU[_P &4W_Q5=(OP)^,#HKK\/\ 5RK#(/E#D?G1
M_P *%^,7_1/=7_[]#_&@#F?^$^\=?]#KKW_@RF_^*H_X3[QU_P!#KKW_ (,I
MO_BJZ;_A0OQB_P"B>ZO_ -^A_C1_PH7XQ?\ 1/=7_P"_0_QH ^S_ -D_5-2U
MCX*27FKZE=:C=?VI.GG74S2OM"QX&6).*]SN+>"\LY;6YA2:"9#')&Z[E=2,
M$$=P17C'[,/A?Q!X/^#DFD^)M(N-*OO[2FE\BX7#%"J8;Z<'\J]SH _/[XT?
MLSZ]X1U"\\1>![*;5O#3L9&M807N+$=2I7JZ#LPR0.O3)^:B"I((P1V-?LM7
MF'CCX%_#'Q]+)<ZUX;B@U"3DW]B?L\Q/J2O#G_>!H _+:BOL;Q-^Q/<*7E\'
M^-$=>=MOJD!4_P#?R/.?^^!7BWBO]G7XN>$4DGN_"LNI6B9)N-+87*X]=J_.
M!]5% 'FVD:[K&@Z@FH:'JMWIEVARLUI,T3C\5(KZ0^&W[7?BC0[F&Q^(%O\
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MG9,!W R00.<'/) % 'Z1T5DZ/KFD^(=+BU30]2MM1L9AE)[:42(?Q'?VK6H
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M@ >U% 'XY4O>OJ/_ (8G^(7_ $-7A[_OJ?\ ^-T?\,3_ !!_Z&GP[_WU/_\
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M_)??&_\ V%I__0J\[K[-^(7[)_C3QA\2O$/B:Q\0:);VVIWLES%',TV]58Y
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MCITJSXLU34O%7@[5_#=C\+=:6[U.UDM8I-0AM8H(7=2!*["5B A(;@$\<<T
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M/#W_ $ =._\  5/\*** .$\/00Z1\9_&&CZ9&MKI\UCINHM;QC"?:))9XI)
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>16L8PD<TT+&5E';<44D#C.3C).2B@#U*BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
